Pictograma "Medicamentos y conducción": comprensión, aceptación y legibilidad. Fármacos oftalmológicos: categorización DRUID

Accidentes de tráfico: serio problema de salud pública. - por personas que fallecen (1126 en año 2015).- por lesiones (temporales o permanentes) que ocasionan.- por sus consecuencias: elevado coste humano, social y económico. Causas multifactoriales. Relacionadas propios conductores y condiciones psicofísicas, más importantes. Medicamentos, derivado de: efectos terapéuticos, secundarios o interacciones, pueden estar relacionados con 5% de accidentes tráfico. España, 2011, medicamentos con posibles efectos sobre capacidad de conducir incorporan pictograma de conducción en envase. Características (RD 1345/2007): fondo blanco, triángulo equilátero rojo (vértice hacia arriba) y coche negro en interior, con leyenda “conducción: ver prospecto”. Tamaño adaptado envase y lado no inferior a 10 mm. Objetivo: llamar atención usuario, para que lea prospecto (4.7: efectos sobre conducción y manejo de maquinaria). De 402 principios activos AEMPS: 20% llevan pictograma (2013). Del grupo S “Órganos de los sentidos”: lo llevan 16 (de 92). Proyecto europeo DRUID (DRiving Under the Influence of Drugs, Alcohol and Medicines). Basado: Criterios estandarizados clasificar fármacos. Sistema clasificación europeo medicamentos. Herramienta prescripción y dispensación e instrumento para usuarios tomen conciencia. Estructurado: 7 áreas; dos relacionadas con Estudio (nuestro país participó a través de UVA): A. 4: Categorización medicamentos en relación a sus efectos sobre conducción. A.7: Actividades de divulgación, directrices y formación personal sanitario. Profesionales sanitarios desarrollan, entre otras, funciones de prevención, información y educación sanitaria. Intervenir “cadena terapéutica del medicamento” conlleva obligaciones de información al paciente. Se puede incurrir en responsabilidad profesional por dejar de advertir precauciones o limitaciones que deba adoptar. Individuo es protagonista de su salud, decide y toma medidas. Labor del profesional sanitario es coadyuvante. Ambos responsabilidad compartida para valorar posibles riesgos y consecuencias graves para él mismo y para resto personas implicadas.Departamento de Biología Celular, Histología y Farmacologí

Actividad donación-trasplante. Hospital Universitario de Son Dureta. 1989-2003

España es el país con la tasa (n° por millón de población) de donaciones y trasplantes de órganos sólidos mayor del mundo. El Hospital Universitario de Son Dureta (HUSD) ha contribuido de forma progresiva e importante a esta actividad desde 1989. El éxito de esta actividad de donación-trasplante de órganos depende del trabajo en equipo de muchos profesionales sanitarios y no sanitarios del hospital y de la Comunidad, con diferentes características y motivaciones. Es como una cadena con múltiples eslabones que no se pueden romper, con una finalidad común y única, que es la extracción de órganos, de pacientes que han evolucionado a la muerte a pesar de nuestros esfuerzos terapéuticos, para su posterior trasplante a pacientes que están en la fase terminal o irreversible de sus enfermedades. Sin un personal sanitario concienciado sobre la importancia de la donación de órganos, es difícil sacar adelante los procesos hospitalarios de donación-trasplante. Actualmente el HUSD esta plenamente identificado con la actividad de donación-trasplante de órganos, después de muchos años de trabajo, esfuerzo e ilusión. Esta actividad médica tiene un componente humano importante, tanto para las familias de los donantes con las que se mantiene un vínculo muy especial, como para los pacientes que están esperando algún órgano. El éxito profesional y social de esta actividad supone un prestigio para todos los profesionales que trabajamos en el HUSD, sus unidades generadoras de donantes y la Comunidad Balear

Extracorporeal membrane oxygenation (ECMO): Initial experience at our hospital for acute severe respiratory failure in adults

La oxigenación por membrana extracorpórea (ECMO) es una forma de soporte vital extracorpóreo. Un circuito o sistema de circulación artificial externo conduce sangre venosa desde el paciente a un oxigenador, donde se añade oxígeno y se desprende dióxido de carbono, y a continuación, la sangre se devuelve a la circulación del paciente. Dependiendo de si su configuración es venovenosa (VV) o venoarterial, la ECMO se utiliza como apoyo temporal de la función respiratoria, de la función circulatoria o de ambas. El objetivo de este artículo es presentar la experiencia inicial del hospital universitario Son Espases (Palma) con el sistema ECMO VV al tratarse del único centro en las Islas Baleares capaz de ofrecer dicho tratamiento.Extracorporeal membrane oxygenation (ECMO) is a form of extracorporeal life support. An external artificial circulation or circuit carries venous blood from the patient to an oxygenator, where oxygen is added and carbon dioxide removed, then the blood is returned to the patient circulation. Depending on its configuration –venovenous (VV) or venoarterial–, ECMO is temporarily used to support respiratory function, circulation, or both. The objective of this publication is to review the initial experience at Son Espases University Hospital (Palma) using VV ECMO, unique centre in the Balearic Island with the capability of providing this therapy

Survival of hematological patients after discharge from the intensive care unit: a prospective observational study

INTRODUCTION: Although the survival rates of hematological patients admitted to the ICU are improving, little is known about the long-term outcome. Our objective was to identify factors related to long-term outcome in hematological patients after ICU discharge. METHODS: A prospective, observational study was carried out in seven centers in Spain. From an initial sample of 161 hematological patients admitted to one of the participating ICUs during the study period, 62 were discharged alive and followed for a median time of 23 (1 to 54) months. Univariate and multivariate analysis were performed to identify the factors related to long term-survival. Finally, variables that influence the continuation of the scheduled therapy for the hematological disease were studied. RESULTS: Mortality after ICU discharge was 61%, with a median survival of 18 (1 to 54) months. In the multivariate analysis, an Eastern Cooperative Oncology Group score (ECOG) >2 at ICU discharge (Hazard ratio 11.15 (4.626 to 26.872)), relapse of the hematological disease (Hazard ratio 9.738 (3.804 to 24.93)) and discontinuation of the planned treatment for the hematological disease (Hazard ratio 4.349 (1.286 to 14.705)) were independently related to mortality. Absence of stem cell transplantation, high ECOG and high Acute Physiology and Chronic Health Evaluation II (APACHE II) scores decreased the probability of receiving the planned therapy for the hematological malignancy. CONCLUSIONS: Both ICU care and post-ICU management determine the long-term outcome of hematological patients who are discharged alive from the ICU

Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998

[Abstract] Background: Myocardial infarction (MI) incidence and mortality display a high geographic variation. Aims: The objective of the present study was to analyze MI mortality, cumulative incidence rate variability in seven regions of Spain from 1997 to 1998. Methods and Results: Standardized methods were used to identify, find, register, and classify MI cases that were classified as definite, possible, insufficient-dataMI, and non-MI. The total population of the seven monitored regions was 7,364,682 inhabitants. Of the 11,256 cases fulfilling eligibility criteria to investigate, 10,660 were selected to calculate MI rates: 6554 (61.5%)non-fatal definite MI, 1179 (11.1%)fatal definite MI, 1859 (17.4%)fatal possible MI, 1068 (10.0%)fatal cases with insufficient data. The IBERICA 25–74 years age-standardized cumulative incidence rates for men and women, were 207 (range: 175–252) and 45 (range: 36–65) per 100,000, respectively. The age-standardized mortality rates for men and women, were 73 (range: 62–94) and 20 (range: 13–29) per 100,000, respectively. Age-standardized case-fatality was 31.4 and 24.2% in men aged 25–74 and 35–64 years, respectively, and 32.7 and 27.0%, respectively, in women. Conclusions: MI cumulative incidence and mortality rates are low compared with other industrialized countries but, vary considerably among regions in a Mediterranean country like Spain.Cataluña. Comissió Interdepartamental de Recerca i Innovació Tecnològica; CIRIT/2001 SGR 00408Instituto de Salud Carlos III; FIS 96/0026-01 to 05Instituto de Salud Carlos III; FIS 97/1270Instituto de Salud Carlos III; FIS 98/153

Recursos hospitalarios y letalidad por infarto de miocardio. Estudio IBERICA

[Abstract] Introduction and objectives. To determine the proportion of patients with myocardial infarction (MI) not admitted to a coronary care unit (CCU), the variables associated with admission into a CCU, and whether admission to a CCU, and the availability of coronary angiography in the same hospital, were associated with 28-day case fatality. Patients and method. Population-based registry of MI in patients 25 to 74 years of age, admitted during 1996-1998. Demographic and clinical characteristics were recorded, as well as management, clinical course and survival after 28 days. Hospitals were classified according to the availability of a CCU and catheterization laboratory (advanced hospital), CCU only (intermediate hospital) or neither (basic hospital). Admission to the CCU was also recorded. Results. In all, 9046 cases of MI were recorded; in 11.3% the patient was not admitted to a CCU. Age, smoking (OR=1.33; 95% CI, 1.08-1.64), non-Q MI (OR=0.62; 95% CI, 0.49-0.78) or undetermined location of MI (OR=0.34; 95% CI, 0.23-0.50), Killip 4 score on admission (OR=0.63; 95% CI, 0.40-1.00) and delay in arrival at the hospital >6 h were associated with CCU admission. Patients admitted to a CCU showed a lower case fatality in the first 24 h (4.2% vs 23.5%), which was independent of comorbidity, severity and treatment. The 24-hour survivors admitted to a basic hospital had higher case fatality (17.3% vs 7.8%) than other groups, which was related to differences in treatment. Conclusions. CCU admission is associated with a lower case fatality in the first 24 h. Admission to a basic hospital is associated with a higher 28-day case fatality even in patients who survive 24 h.[Resumen] Introducción y objetivos. Determinar el porcentaje de pacientes con infarto agudo de miocardio (IAM) que no ingresan en una unidad de cuidados intensivos coronaries (UCIC), las variables asociadas al ingreso en una UCIC y si el ingreso en una UCIC, su disponibilidad y la de hemodinámica en el hospital se asocian a la letalidad a 28 días. Pacientes y método. Registro poblacional (1996-1998) de casos de IAM en pacientes con edades comprendidas entre los 25 y los 74 años. Se recogieron variables demográficas, clínicas, el ingreso en UCIC y la letalidad a los 28 días. Se clasificaron los hospitales según la disponibilidad de UCIC y hemodinámica (hospital avanzado), solamente UCIC (hospital intermedio) o ninguno (hospital básico). Resultados. Se registraron 9.046 casos; el 11,3% no ingresó en una UCIC. La edad, el consumo de tabaco (odds ratio [OR] = 1,33; intervalo de confianza [IC] del 95%, 1,08-1,64), el infarto sin onda Q (OR = 0,62; IC del 95%, 0,49-0,78) o ilocalizable (OR = 0,34; IC del 95%, 0,23-0,50), el grado Killip 4 al ingreso (OR = 0,63; IC del 95%, 0,40-1,00) y el retraso > 6 h en llegar al hospital se asociaron al ingreso en UCIC. Los pacientes ingresados en UCIC presentaban menor letalidad que los ingresados en hospitales básicos en las primeras 24 h (el 4,2 frente al 23,5%), independientemente de la gravedad del IAM y de las variables relacionadas con el tratamiento. Los su-pervivientes a 24 h que ingresaban en un hospital bÁsico presentaban mayor letalidad a los 28 días (el 17,3 frente al 7,8%), relacionada con las variables de tratamiento. Conclusiones. El ingreso en una UCIC se asocia a una menor letalidad de los pacientes con IAM en las primeras 24 h. El ingreso en un hospital bÁsico se asocia a una mayor letalidad a los 28 días.Insituto de Salud Carlos III; FIS96/0026-01 to 05Insituto de Salud Carlos III; FIS97/1270Insituto de Salud Carlos III; FIS98/153

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

Introduction: Bronchial aspirates (BAS) obtained during invasive mechanical ventilation (IMV) constitutes a useful tool for molecular phenotyping and decision making. Aim: To identify the proteomic determinants associated with disease pathogenesis, all-cause mortality and respiratory sequelae in BAS samples from critically ill patients with SARS-CoV-2-induced ARDS. Methods: Multicenter study including 74 critically ill patients with COVID-19 and non-COVID-19 ARDS. BAS were obtained by bronchoaspiration after IMV initiation. Three hundred sixty-four proteins were quantified using proximity extension assay (PEA) technology. Random forest models were used to assess predictor importance. Results: After adjusting for confounding factors, CST5, NADK, SRPK2 and TGFa were differentially detected in COVID-19 and non-COVID-19 patients. In random forest models for COVID-19, CST5, DPP7, NADK, KYAT1 and TYMP showed the highest variable importance. In COVID-19 patients, reduced levels of ENTPD2 and PTN were observed in nonsurvivors of ICU stay, even after adjustment. AGR2, NQO2, IL-1a, OSM and TRAIL showed the strongest associations with in-ICU mortality and were used to construct a proteinbased prediction model. Kaplan-Meier curves revealed a clear separation in mortality risk between subgroups of PTN, ENTPD2 and the prediction model. Cox regression models supported these findings. In survivors, the levels of FCRL1, NTF4 and THOP1 in BAS samples obtained during the ICU stay correlated with lung function (i.e., DLCO levels) 3 months after hospital discharge. Similarly, Flt3L and THOP1 levels were correlated with radiological features (i.e., TSS). These proteins are expressed in immune and nonimmune lung cells. Poor host response to viral infectivity and an inappropriate reparative mechanism seem to be linked with the pathogenesis of the disease and fatal outcomes, respectively. Conclusion: BAS proteomics identified novel factors associated with the pathology of SARS-CoV-2-induced ARDS and its adverse outcomes. BASbased protein testing emerges as a novel tool for risk assessment in the ICU

The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation

Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort

Background Acute respiratory distress syndrome (ARDS) can be classified into sub-phenotypes according to different inflammatory/clinical status. Prognostic enrichment was achieved by grouping patients into hypoinflammatory or hyperinflammatory sub-phenotypes, even though the time of analysis may change the classification according to treatment response or disease evolution. We aimed to evaluate when patients can be clustered in more than 1 group, and how they may change the clustering of patients using data of baseline or day 3, and the prognosis of patients according to their evolution by changing or not the cluster.Methods Multicenter, observational prospective, and retrospective study of patients admitted due to ARDS related to COVID-19 infection in Spain. Patients were grouped according to a clustering mixed-type data algorithm (k-prototypes) using continuous and categorical readily available variables at baseline and day 3.Results Of 6205 patients, 3743 (60%) were included in the study. According to silhouette analysis, patients were grouped in two clusters. At baseline, 1402 (37%) patients were included in cluster 1 and 2341(63%) in cluster 2. On day 3, 1557(42%) patients were included in cluster 1 and 2086 (57%) in cluster 2. The patients included in cluster 2 were older and more frequently hypertensive and had a higher prevalence of shock, organ dysfunction, inflammatory biomarkers, and worst respiratory indexes at both time points. The 90-day mortality was higher in cluster 2 at both clustering processes (43.8% [n = 1025] versus 27.3% [n = 383] at baseline, and 49% [n = 1023] versus 20.6% [n = 321] on day 3). Four hundred and fifty-eight (33%) patients clustered in the first group were clustered in the second group on day 3. In contrast, 638 (27%) patients clustered in the second group were clustered in the first group on day 3.Conclusions During the first days, patients can be clustered into two groups and the process of clustering patients may change as they continue to evolve. This means that despite a vast majority of patients remaining in the same cluster, a minority reaching 33% of patients analyzed may be re-categorized into different clusters based on their progress. Such changes can significantly impact their prognosis